JP2023540799A5 - - Google Patents

Info

Publication number
JP2023540799A5
JP2023540799A5 JP2023516074A JP2023516074A JP2023540799A5 JP 2023540799 A5 JP2023540799 A5 JP 2023540799A5 JP 2023516074 A JP2023516074 A JP 2023516074A JP 2023516074 A JP2023516074 A JP 2023516074A JP 2023540799 A5 JP2023540799 A5 JP 2023540799A5
Authority
JP
Japan
Prior art keywords
cdr3
cdr1
cdr2
cancer
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023516074A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023540799A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/049769 external-priority patent/WO2022056199A1/en
Publication of JP2023540799A publication Critical patent/JP2023540799A/ja
Publication of JP2023540799A5 publication Critical patent/JP2023540799A5/ja
Pending legal-status Critical Current

Links

JP2023516074A 2020-09-11 2021-09-10 多重特異性免疫標的化分子及びその使用 Pending JP2023540799A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063077458P 2020-09-11 2020-09-11
US202063077407P 2020-09-11 2020-09-11
US202063077415P 2020-09-11 2020-09-11
US63/077,407 2020-09-11
US63/077,415 2020-09-11
US63/077,458 2020-09-11
US202163165050P 2021-03-23 2021-03-23
US63/165,050 2021-03-23
PCT/US2021/049769 WO2022056199A1 (en) 2020-09-11 2021-09-10 Multi-specific immune targeting molecules and uses thereof

Publications (2)

Publication Number Publication Date
JP2023540799A JP2023540799A (ja) 2023-09-26
JP2023540799A5 true JP2023540799A5 (cg-RX-API-DMAC7.html) 2024-09-19

Family

ID=80629898

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023516074A Pending JP2023540799A (ja) 2020-09-11 2021-09-10 多重特異性免疫標的化分子及びその使用

Country Status (11)

Country Link
US (2) US20220089737A1 (cg-RX-API-DMAC7.html)
EP (1) EP4211172A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023540799A (cg-RX-API-DMAC7.html)
KR (1) KR20230084507A (cg-RX-API-DMAC7.html)
AU (1) AU2021338776A1 (cg-RX-API-DMAC7.html)
CA (1) CA3194752A1 (cg-RX-API-DMAC7.html)
IL (1) IL301242A (cg-RX-API-DMAC7.html)
MX (1) MX2023002945A (cg-RX-API-DMAC7.html)
TW (1) TW202227494A (cg-RX-API-DMAC7.html)
UY (1) UY39416A (cg-RX-API-DMAC7.html)
WO (1) WO2022056199A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2983898A1 (en) * 2015-04-28 2016-11-03 Mitsubishi Tanabe Pharma Corporation Rgma binding protein and use thereof
CN119954959A (zh) 2019-03-11 2025-05-09 詹森生物科技公司 抗Vβ17/抗CD123双特异性抗体
US11919958B2 (en) 2020-08-19 2024-03-05 Xencor, Inc. Anti-CD28 compositions
WO2022056197A1 (en) * 2020-09-11 2022-03-17 Janssen Biotech, Inc. Immune targeting molecules and uses thereof
UY39415A (es) 2020-09-11 2022-03-31 Janssen Biotech Inc Métodos y composiciones para modular la inmunidad mediada por cadenas beta
WO2022175255A2 (en) 2021-02-16 2022-08-25 Janssen Pharmaceutica Nv Trispecific antibody targeting bcma, gprc5d, and cd3
IL314993A (en) 2022-02-23 2024-10-01 Xencor Inc Anti-cd28 x anti-psma antibodies
CN119255825A (zh) * 2022-05-24 2025-01-03 第一三共株式会社 抗-cdh6抗体-药物缀合物的剂量方案
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024040220A2 (en) * 2022-08-19 2024-02-22 Regents Of The University Of Minnesota Cd83 binding fusion proteins
WO2024040228A2 (en) * 2022-08-19 2024-02-22 Regents Of The University Of Minnesota Cd83 binding proteins
AU2024217296A1 (en) * 2023-02-09 2025-09-25 Janssen Biotech, Inc. Anti-v beta 17/anti-cd123 bispecific antibodies
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
CN117187180B (zh) * 2023-11-03 2024-01-26 四川大学 一种Th17细胞及其培养方法和应用及其诱导液
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2026136805A1 (en) * 2024-12-19 2026-06-25 Agni Bio, Inc. Methods and compositions for modulating v-beta-17 chain mediated immunity

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200724548A (en) * 2005-04-25 2007-07-01 Pfizer Antibodies to myostatin
WO2009139822A1 (en) * 2008-05-01 2009-11-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
US9790274B2 (en) * 2013-03-14 2017-10-17 The Board Of Regents Of The University Of Texas System Monoclonal antibodies targeting EpCAM for detection of prostate cancer lymph node metastases
BR112017000939A2 (pt) * 2014-07-21 2017-11-14 Novartis Ag tratamento de câncer usando um receptor antigênico quimérico de cll-1
WO2016167306A1 (ja) * 2015-04-16 2016-10-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗ヒトNotch4抗体
JO3711B1 (ar) * 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
US10800843B2 (en) * 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
AU2016332900C1 (en) * 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
US11370830B2 (en) * 2017-04-07 2022-06-28 The Rockefeller University Neutralizing antibodies that bind to the zika virus domain III envelope region
US12564632B2 (en) * 2017-11-08 2026-03-03 Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. Conjugates of biomolecule and use thereof
SG11202012653XA (en) * 2018-06-19 2021-01-28 Biontech Us Inc Neoantigens and uses thereof
WO2020010250A2 (en) * 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
JP7700039B2 (ja) * 2019-01-04 2025-06-30 マレンゴ・セラピューティクス,インコーポレーテッド 抗tcr抗体分子およびその使用
CN119954959A (zh) * 2019-03-11 2025-05-09 詹森生物科技公司 抗Vβ17/抗CD123双特异性抗体
CA3143995A1 (en) * 2019-06-21 2020-12-24 Single Cell Technology, Inc. Anti-tigit antibodies
WO2021064671A1 (en) * 2019-10-03 2021-04-08 Janssen Biotech, Inc. Methods for producing biotherapeutics with increased stability by sequence optimization
CA3173268A1 (en) * 2020-02-27 2021-09-02 Janssen Biotech, Inc. Materials and methods for modulating an immune response

Similar Documents

Publication Publication Date Title
Weiner et al. Monoclonal antibodies for cancer immunotherapy
JP2015214582A5 (cg-RX-API-DMAC7.html)
JPWO2019189780A5 (cg-RX-API-DMAC7.html)
JP2018518454A5 (cg-RX-API-DMAC7.html)
JP2015534578A5 (cg-RX-API-DMAC7.html)
JP2016502504A5 (cg-RX-API-DMAC7.html)
JP2018535692A5 (cg-RX-API-DMAC7.html)
JP2020501531A5 (cg-RX-API-DMAC7.html)
JP2015532292A5 (cg-RX-API-DMAC7.html)
JP2015509947A5 (cg-RX-API-DMAC7.html)
JP2017517506A5 (cg-RX-API-DMAC7.html)
JP2018027952A5 (cg-RX-API-DMAC7.html)
MX2017014740A (es) Métodos de tratamiento del cáncer con anticuerpos anti-ox40.
MX2022002524A (es) Formulaciones farmaceuticas y regimenes de dosificacion para proteinas de union multiespecificas que se unen a her2, nkg2d y cd16 para el tratamiento del cancer.
JP2023540796A5 (cg-RX-API-DMAC7.html)
JP2009521496A5 (cg-RX-API-DMAC7.html)
JP2014240385A5 (cg-RX-API-DMAC7.html)
JP2019506398A5 (cg-RX-API-DMAC7.html)
JP2019506403A5 (cg-RX-API-DMAC7.html)
NZ604007A (en) Monoclonal antibodies against her2 epitope
MA44560B1 (fr) Anticorps anti-cd38 spécifiques pour le traitement de cancers humains
RU2014138040A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
RU2014101669A (ru) Агенты, связывающие белки r-спондины (rspo), и способы их применения
JP2018508509A5 (cg-RX-API-DMAC7.html)
HRP20171758T1 (hr) Kombinacija dr5 agonista i anti-pd-1 antagonista i načini primjene